Download PDF
Aktuelle Urol 2013; 44(01): 45-49
DOI: 10.1055/s-0032-1323745
Konsensuskonferenz
© Georg Thieme Verlag KG Stuttgart · New York

Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms

Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma
K. Miller
1   Klinik für Urologie, Charité – Universitätsmedizin Berlin
,
L. Bergmann
2   Medizinische Klinik II, J.W. Goethe-Universität Frankfurt/Main
,
J. Gschwend
3   Urologische Klinik und Poliklinik der Technischen Universität München Klinikum rechts der Isar
,
U. Keilholz
4   Medizinische Klinik II, Charité – Universitätsmedizin Berlin
,
M. Kuczyk
5   Klinik für Urologie und onkologische Urologie der Medizinischen Hochschule Hannover
,
M. Wirth
6   Klinik und Poliklinik für Urologie – Universitätsklinikum Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
26 September 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zielgerichtete Substanzen wie Sunitinib, Pazopanib, Bevacizumab, Sorafenib und Everolimus haben sich als Standard beim metastasierten Nierenzellkarzinom etabliert. Weitere Medikamente werden das Spektrum der Behandlungsoptionen erweitern. Der Einsatz von Zytokinen als langjährige Standardtherapie rückt damit in den Hintergrund. Mit den erreichten Fortschritten stellen sich im Praxisalltag jedoch auch ganz neue Fragen: Welche Kriterien sind wichtig für die Therapieentscheidung? Wie wird eine Remission unter anti-angiogenetischer Therapie beurteilt? Und nicht zuletzt bleibt auch die Sequenz ein intensiv diskutiertes Thema. Anhand der aktuellen Datenlage wurden diese Aspekte im Rahmen eines Expertenmeetings besprochen. Das interdisziplinäre Board knüpfte an Therapieempfehlungen aus dem Jahr 2011 an [1]. Das Ergebnis der Diskussion wird hier in Form von Thesen und einem Therapiealgorithmus zusammengefasst.

Abstract

Targeted therapies such as sunitinib, pazopanib, bevacizumab, sorafenib and everolimus have become established as new therapeutic standards in the treatment of metastatic renal cell carcinoma. New substances are going to complement these treatment options. Therefore, cytokines as long-term standard therapy are being more and more replaced. The achievements raise a lot of questions in clinical daily routine: Which criteria influence the decision for therapy? How can a remission be assessed when antiangiogenetic agents are administered? And last but not least, the optimal sequence remains a controversially discussed topic. Based on the current study situation, an interdisciplinary expert meeting was held to debate these aspects. Results from the 2010 conference provided the basis for the 2011 meeting. The results of the 2011 conference are presented as short theses.

Schlüsselwörter

zielgerichtete Substanzen - Nierenzellkarzinom - Zytokinen - Behandlungsoptionen - Expertenmeeting

Key words

targeted therapies - renal cell carcinoma - cytokines - treatment options - expert meeting
 

  • Literatur

  • 1 Miller K, Bergmann L, Gschwend J et al. Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms. Aktuel Urol 2011; 42: 1-5
    PubMedGoogle Scholar
  • 2 Krebs in Deutschland 2007/2008 . Robert Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., 8. Ausgabe 2012;
    PubMedGoogle Scholar
  • 3 Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124
    CrossrefPubMedGoogle Scholar
  • 4 Sternberg C, Davis ID, Mardiak J et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010; 38 (06) 1061-1068
    PubMedGoogle Scholar
  • 5 Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; Dec 22; 370 (9605) 2103-2111
    PubMedGoogle Scholar
  • 6 Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134
    CrossrefPubMedGoogle Scholar
  • 7 Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (22) 3584-3590
    CrossrefPubMedGoogle Scholar
  • 8 Sternberg CN, Hawkins RE, Szczylik C et al. Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): Final overall survival (OS) results. Ann Oncol 2010; 21 (Suppl. 08) viii10 (ESMO 2010, Abstr. #LBA22)
    PubMedGoogle Scholar
  • 9 Bukowski RM, Negrier S, Elson P et al. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 2004; 10: 6310-6314
    CrossrefPubMedGoogle Scholar
  • 10 Coppin C, Porzsolt F, Kumpf J et al. Immunotherapy for advanced renal cell cancer. Cochrane Database SystRev 2005; (01) CD001425
    PubMedGoogle Scholar
  • 11 Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 20. 289-296
    PubMedGoogle Scholar
  • 12 NICE. 2010 http://www.nice.org.uk/nicemedia/live/12032/52299/52299.pdf
    PubMed
  • 13 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
    CrossrefPubMedGoogle Scholar
  • 14 Motzer RJ, Michaelson MD, Hutson TE et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. Eur J Cancer 2007; 5 (4S) 301-301
    PubMedGoogle Scholar
  • 15 Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134
    CrossrefPubMedGoogle Scholar
  • 16 Motzer R, Escudier B, Oudard S et al. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456
    CrossrefPubMedGoogle Scholar
  • 17 Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-763
    CrossrefPubMedGoogle Scholar
  • 18 Rosenberg JE, Michaelson MD, Redman BG et al. Sunitinib therapy for patients with metastatic renal cell carcinoma: updated results of two phase II trials and prognostic factor analysis for survival. ASCO 2007; poster 5095
    PubMedGoogle Scholar
  • 19 George DJ, Michaelson MD, Rosenberg JE et al. Sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). Eur J Cancer 2007; 5: 304
    PubMedGoogle Scholar
  • 20 Rini BI, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. J Clin Oncol 2011 29 (suppl; abstr. 4503)
    PubMedGoogle Scholar
  • 21 Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188-1194
    CrossrefPubMedGoogle Scholar
  • 22 McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141
    CrossrefPubMedGoogle Scholar
  • 23 Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’Immunotherapie. N Engl J Med 1998; 338: 1272-1278
    CrossrefPubMedGoogle Scholar
  • 24 Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867
    PubMedGoogle Scholar
  • 25 Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of Sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512
    CrossrefPubMedGoogle Scholar
  • 26 Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434
    CrossrefPubMedGoogle Scholar
  • 27 Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21 (16) 3127-3122
    CrossrefPubMedGoogle Scholar
  • 28 Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-763
    CrossrefPubMedGoogle Scholar
  • 29 Beck J, Bajetta E, Escudier B et al. A large open-label non-comparative phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma. ECCO 2007; Abstract 4506
    PubMedGoogle Scholar
  • 30 Dutcher JP, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (advRCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No.18 S (June20Supplement) 5033
    PubMedGoogle Scholar
  • 31 Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131
    CrossrefPubMedGoogle Scholar
  • 32 Fachinformation TORISEL® 25 mg Konzentrat, Pfizer Pharma GmbH, September 2011
    PubMed
  • 33 Fachinformation SUTENT® 12,5/25/37,5/50 mg Hartkapseln, Pfizer Pharma GmbH, January 2012
    PubMed
  • 34 Fachinformation AVASTIN®, Roche Pharma AG, Februar 2012
    PubMed
  • 35 Fachinformation ROFERON®-A 18 Mio. I.E./0,6 ml Patrone mit Injektionslösung, Roche Pharma AG, August 2011
    PubMed
  • 36 Fachinformation VOTRIENT® 200/400 mg Filmtabletten, GlaxoSmithKline GmbH, März 2012
    PubMed
  • 37 Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized phase III trial of Sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. ASCO2007 Abstract 5023. J Clin Oncology 2007; ASCO Annual Meeting Proceedings Part I Vol 25, No.18 S (June 20 Supplement), 2007: 5023
    PubMedGoogle Scholar
  • 38 Tamaskar I, Garcia JA et al. Antitumor effects of sunitinib or Sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 81-86
    PubMedGoogle Scholar
  • 39 Rini BI, Hutson TE, Elson P et al. Phase II Study of Sorafenib in patients with mRCC refractory to Sunitinib or Bevacizumab. ASCO GU 2008; Abstract 346
    PubMedGoogle Scholar
  • 40 Di Lorenzo G, Buonerba C, Federico P et al. Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. J Clin Oncol 2009; 27: 4469-4474
    CrossrefPubMedGoogle Scholar
  • 41 Shepard DR, Rini BI, Garcia A et al. A multicentre prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008; 26: 280 Abstr. 5123
    PubMedGoogle Scholar
  • 42 Rini BI, Wilding G, Hudes G et al. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. JCO 2009; 27 (27) 4462-4468
    CrossrefPubMedGoogle Scholar
  • 43 Grünwald V, Fenner M, Seidel C et al. Antitumor activity of sequential treatment with tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010; 28 (suppl; abstr e15132)
    PubMedGoogle Scholar
  • 44 Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071-1076 CinicalTrials.gov Identifier: NCT00930033
    CrossrefPubMedGoogle Scholar
  • 45 Johannsen M, Flörcken A, Bex A et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol Jun 2009; 55 (06) 1430-1438 (Epub 2008 Oct18)
    CrossrefPubMedGoogle Scholar
  • 46 Hainsworth JD, Spigel DR, Burris HA et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol May 2010; (13) 2131-2136 (Epub 2010 Apr 5)
    PubMedGoogle Scholar
  • 47 Karakiewicz PI, Suardi N, Jeldres C et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma a trial thrombi. Eur Urol 2008; 53: 845-848
    CrossrefPubMedGoogle Scholar
  • 48 CM T, Uzzo RG, Wood CG et al. Adjuvant and neoadjuvant therapy for renal cell carcinoma: A survey of the Society of Urologic Oncology. Urol Oncol Jan 19 2012; (Epub ahead of print)
    PubMedGoogle Scholar
  • 49 Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol Aug 2011; 6 (03) 144-150
    CrossrefPubMedGoogle Scholar
  • 50 Bex A, Jonasch E, Kirkali Z et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 58 (06) 819-828
    PubMedGoogle Scholar
  • 51 Jonasch E, Tsavachdidou D, Wood CG et al. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 4076-4081
    CrossrefPubMedGoogle Scholar
  • 52 Thomas AA, Rini BI, Stephenson AJ et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009; 182: 881-886
    CrossrefPubMedGoogle Scholar
  • 53 Cowey CL, Armin C, Pruthi RS et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010; 28 (09) 1502-1507
    CrossrefPubMedGoogle Scholar
  • 54 Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumournephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92: 843-846
    CrossrefPubMedGoogle Scholar